Objective: This paper describes two different clinical presentations of diffuse cutaneous mastocytosis (DCM), based on the largest series published to date. As far as we are aware, these two variants of clinical presentations have not yet been reported. Design: We undertook a case controlled analysis of 8 children with DCM. Results of laboratory testing including mast cell mediator levels, and clinical symptoms on presentation and during follow-up were analyzed. Results: The levels of relevant mast cell mediators were initially high in all cases but declined sharply later on. There was a reduction of 20% in 2 of the 7 cases, whereas there was a reduction of 80% in the remaining 5. No reduction occurred in 1 case. Clinical improvement followed the same pattern. Conclusions: DCM is a rare variant of cutaneous childhood onset mastocytosis. Various forms show the same or overlapping features at various times. It appears to follow a course similar to that in other types of childhood onset mastocytosis, taking into account the decreased symptoms and the levels of mast cell mediators during follow-up. Obtaining a bone marrow biopsy should be considered only in those cases where there is no improvement or even worsening of signs or symptoms and persistent elevated levels of mast cell mediators.

Keywords:
Diffuse cutaneous mastocytosis, children, Clinical presentation, variants, Mast cell mediator
1.
Valent P, Horny HP, Escribano L, et al: Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference report of Year 2000 Working Conference on Mastocytosis. Leuk Res 2001;25:603–625.
2.
Valent P, Horny HP, Li CY, et al: Mastocytosis (mast cell disease): World Health Organization (WHO) classification of tumours, pathology and genetics; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, vol 1, pp 291–302.
3.
Valent P, Akin C, Escribano L, et al: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435–453.
4.
Orfao A, Garcia-Montero AC, Sanchez L, Escribano L, for the Spanish Network on Mastocytosis (REMA): Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12–30.
5.
Hartmann K, Metcalfe DD: Pediatric mastocytosis. Hematol Oncol Clin North Am 2000;14:625–640.
6.
Hartmann K, Henz BM: Classification of cutaneous mastocytosis: a modified consensus proposal. Leuk Res 2002;26:483–484.
7.
Middelkamp Hup MA, Heide R, Tank B, et al: Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol 2002;16:115–120.
8.
Heide R, Tank B, Oranje AP: Mastocytosis in childhood. Pediatr Dermatol 2002;19:375–381.
9.
Ben-Amitai D, Metzker A, Cohen HA: Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J 2005;7:320–322.
10.
Hannaford R, Rogers M: Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol 2001;42:15–21.
11.
Van Gysel D, Oranje AP, Vermeiden I, et al: Value of urinary N-methylhistamine measurements in childhood mastocytosis. J Am Acad Dermatol 1996;35:556–558.
12.
Verzijl A, Heide R, Oranje AP, van Schaik RHN: c-kit Asp-816-Val analysis in patients with mastocytosis. Dermatology 2000;214:15–20.
13.
Kiujken I, Bergman W, Oranje AP: Diffuse cutaneous mastocytosis (in Dutch). Ned Tijdschr Geneeskd 2001;145:1527.
14.
Oranje AP, Soekanto W, Sukardi A, et al: Diffuse cutaneous mastocytosis mimicking staphylococcal scalded-skin syndrome: report of three cases. Pediatr Dermatol 1991;8:147–151.
15.
van Toorenenbergen AW, Oranje AP: Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta 2005;359:72–77.
16.
Inamadar AC, Palit A: Diffuse cutaneous mastocytosis. Indian J Dermatol Venereol Leprol 2006;72:50–53.
17.
Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, et al: Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol 2004;18:285–290.
18.
Has C, Misery L, David L, Cambazard F: Recurring staphylococcal scalded skin syndrome-like bullous mastocytosis: the utility of cytodiagnosis and the rapid regression with steroids. Pediatr Dermatol 2002;19:220–223.
19.
Golitz LE, Weston WL, Lane AT: Bullous mastocytosis: diffuse cutaneous mastocytosis with extensive blisters mimicking scalded skin syndrome or erythema multiforme. Pediatr Dermatol 1984;1:288–294.
20.
Verma KK, Bhat R, Singh MK: Bullous mastocytosis treated with oral betamethasone therapy. Indian J Pediatr 2004;71:261–263.
21.
Husak R, Blume-Peytavi U, Pfrommer C, et al: Nodular and bullous cutaneous mastocytosis of the xanthelasmoid type: case report. Br J Dermatol 2001;144:355–358.
22.
Rajesh J, Dogra S, Verma S, et al: Diffuse cutaneous mastocytosis: pseudoxanthomatous variant. J Dermatol 2002;29:354–356.
23.
Walker T, von Komorowski G, Scheurlen W, Dorn-Beineke A, Back W, Bayerl C: Neonatal mastocytosis with pachydermic bullous skin without c-kit 816 mutation. Dermatology 2006;212:70–72.
24.
Shah PY, Sharma V, Worobec AS, et al: Congenital bullous mastocytosis with myeloproliferative disorder and c-kit mutation. J Am Acad Dermatol 1998;39:119–121.
25.
Waxtein LM, Vega-Memije ME, Cortes-Franco R, Dominguez-Soto L: Diffuse cutaneous mastocytosis with bone marrow infiltration in a child: a case report. Pediatr Dermatol 2000;17:198–201.
26.
Smith ML, Orton PW, Chu H, Weston WL: Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol 1990;7:251–255.
27.
Kinsler VA, Hawk JL, Atherton DJ: Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy. Br J Dermatol 2005;152:179–180.
28.
Brockow K, Akin C, Huber M, Metcalfe DD: IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005;115:216–223.
29.
Heide R, Beishuizen A, de Groot H, et al: Mastocytosis in children: a protocol for management. Pediatr Dermatol 2008;25:493–500.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.